Evidence map›Paper›PMID 35735729›Full record

ArticleGels (Basel, Switzerland)2022

Design and Development of Neomycin Sulfate Gel Loaded with Solid Lipid Nanoparticles for Buccal Mucosal Wound Healing.

Khaled M Hosny, N Raghavendra Naveen, Mallesh Kurakula, Amal M Sindi, Fahad Y Sabei, Adel Al Fatease, Abdulmajeed M Jali, Waleed S Alharbi, Rayan Y Mushtaq, Majed Felemban and 3 more

Open access · goldAbstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. QbD driven targeted pulmonary delivery of dexamethasone-loaded chitosan microspheres: Biodistribution and pharmacokinetic study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Khaled M HosnyDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-4904-1378
N Raghavendra NaveenDepartment of Pharmaceutics, Sri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B.G. Nagar 571448, Karnataka, India.
Mallesh KurakulaProduct Development Department, CURE Pharmaceutical, Oxnard, CA 93033, USA.ORCID 0000-0002-8130-7068
Amal M SindiDepartment of Oral Diagnostic Science, Faculty of Dentistry, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-5286-1756
Fahad Y SabeiDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia.ORCID 0000-0002-1412-5299
Adel Al FateaseDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia.ORCID 0000-0002-4608-5949
Abdulmajeed M JaliDepartment of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 82511, Saudi Arabia.
Waleed S AlharbiDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-7727-6126
Rayan Y MushtaqDepartment of Pharmaceutics, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.ORCID 0000-0001-5317-1135
Majed FelembanDepartment of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Hossam H TayebNanomedicine Unit, Center of Innovation in Personalised Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0001-8293-5536
Eman AlfayezDepartment of Oral Biology, Faculty of Dentistry, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
Waleed Y RizgDepartment of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-3088-4084
King Abdulaziz University · SAJazan University · SAImam Abdulrahman Bin Faisal University · SAKing Khalid University · SAPharmaceutical Product Development (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug administration to the wound site is a potential method for wound healing. The drug retention duration should be extended, and drug permeability through the buccal mucosal layer should be regulated. Oral wounds can be caused by inflammation, ulcers, trauma, or pathological lesions; if these wounds are not treated properly, they can lead to pain, infection, and subsequent undesirable scarring. This study aimed to develop Kolliphor-407 P-based gel containing neomycin sulfate (NES) loaded in solid lipid nanoparticles (SLNs) and enhance the antimicrobial activity. By considering lipid concentrations and achieving the lowest particle size (Y1) and maximum entrapment (EE-Y2) effectiveness, the formulation of NES-SLN was optimized using the Box-Behnken design. For the selected responses, 17 runs were formulated (as anticipated by the Design-Expert software) and evaluated accordingly. The optimized formulation could achieve a particle size of 196.25 and EE of 89.27% and was further utilized to prepare the gel formulation. The NES-SLN-G formula was discovered to have a smooth, homogeneous structure and good mechanical and rheological properties. After 24 h of treatment, NES-SLN-G showed a regulated in vitro drug release pattern, excellent ex vivo permeability, and increased in vitro antibacterial activity. These findings indicate the potential application of NES-SLN-loaded gels as a promising formulation for buccal mucosal wound healing.

Indexed as

gelshealth careneomycin sulfateoptimizationsolid lipid nanoparticlessustainability of natural resourceswound healing

Identifiers

PMID35735729
PMCPMC9222678
OpenAlexW4283024221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.